Transcript: METABOLIC RESPONSE OF PAEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMA CELLS TO PI3K INHIBITION DETECTED BY 2H-MRS

Alex: Welcome to another episode of ResearchPod. Today, we're looking at a study on monitoring aggressive pediatric brain tumors — the kind that are particularly difficult to treat and even harder to track.

Sam: That's right. The specific type is called diffuse high-grade glioma. These are fast-growing tumors in the brain, and one of the biggest problems with treating them is that doctors have no quick way to know if a treatment is actually working. Standard MRI scans can take months to show any visible change in tumor size.

Alex: So you could be giving a child a treatment for months, not knowing if it's helping at all?

Sam: Exactly. And that's the core problem this paper is trying to solve. The researchers wanted to find a way to tell within just twenty-four hours whether a therapy is doing its job — not by waiting for the tumor to shrink, but by watching something more immediate.

Alex: What's that something more immediate?

Sam: Energy. Specifically, how fast tumor cells are burning fuel to survive and grow. Every living cell needs energy to function, and it gets that energy by breaking down sugar — a process called glycolysis. Think of it like a car engine burning gasoline. If the engine stops burning fuel, the car stops moving. Tumor cells are especially hungry engines — they burn through sugar at a much faster rate than normal cells.

Alex: So if you could see the tumor's fuel consumption drop, that would tell you the treatment is working — even before the tumor visibly shrinks?

Sam: Precisely. And that's what this technique does. It's called Deuterium Magnetic Resonance Spectroscopy. Here's how it works: the researchers replaced the normal hydrogen atoms in a glucose molecule with a heavier version of hydrogen called deuterium. When tumor cells break down that tagged glucose, the waste products — like a substance called lactate — carry the deuterium label with them. A special scanner can detect that label, which means you can watch, in real time, how fast the tumor is consuming sugar and producing waste.

Alex: It's like putting a dye in the fuel tank so you can track exactly where it goes.

Sam: That's a good way to put it. And when they applied a drug treatment to the tumor cells, the results were telling. The drug blocks something called the PI3K/mTOR pathway — think of it as a master control switch that tells the tumor cell how much energy to demand. When that switch was turned off, the cells almost immediately reduced their sugar consumption.

Alex: So the metabolism drops before the cell actually dies?

Sam: That's the key finding. At the twenty-four hour mark, the cells were still alive — but their fuel consumption had already fallen significantly. The signaling pathway that was telling them to keep eating had been disabled. They were effectively being starved, even though they hadn't yet died.

METABOLIC RESPONSE OF PAEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMA CELLS TO PI3K INHIBITION DETECTED BY 2H-MRS

Declan J. Bolster, James O'Keeffe, Upasana Roy, Aidan M. Michaels, Rebecca Rogers, Diana Martins Carvalho, Maggie Lui, Amin Mirza, Yann Jamin, Carol Box, Chris Jones, Thomas Eykyn, Simon Robinson, Jessica K. R. Boult

Nov 26, 2024·3:29·openalex·Original Paper

2H-MRSPaediatric-type diffuse high grade glioma (PDHGG)PI3K inhibitionGlycolytic rateEarly metabolic biomarker

Listen

3 min

Briefing

Research Objective

Paediatric-type diffuse high-grade glioma (PDHGG) is an aggressive brain cancer where conventional MRI often fails to show treatment efficacy for months. This study investigates whether deuterium metabolic imaging, specifically 2H-MRS (deuterium magnetic resonance spectroscopy), can detect metabolic changes in cancer cells much earlier than traditional anatomical imaging. The researchers focused on how these cells respond to PI3K/mTOR inhibition, a targeted therapy pathway often implicated in tumor growth.

Methodology

The researchers used PDHGG neurospheres—three-dimensional cell cultures that mimic the structure and behavior of brain tumors—carrying a PIK3R1 mutation. These cells were treated with a dual PI3K/mTOR inhibitor. To track metabolic activity, the team introduced deuterated glucose ([6,6-2H2]-glucose) into the culture medium. They then used 2H-MRS to dynamically acquire spectra, allowing them to measure the rate at which the cells consumed glucose and converted it into metabolic byproducts like lactate. These measurements were taken at 24 and 72 hours post-treatment.

Key Findings

The study found that the PI3K/mTOR inhibitor caused a significant reduction in glycolytic rates at both the 24-hour and 72-hour marks. Crucially, at the 24-hour timepoint, there was no measurable change in cell number or overall viability. This indicates that the metabolic shift occurred well before any physical reduction in tumor mass or cell death was detectable. By identifying this "metabolic signature" of drug response, the researchers demonstrated that 2H-MRS can serve as an early, sensitive biomarker for treatment efficacy.

Why It Matters

This research provides a proof-of-concept for using deuterium metabolic imaging to monitor cancer treatment in real-time. Because current clinical standards rely on observing changes in tumor size, patients often remain on ineffective therapies for months. If 2H-MRS can be successfully translated to in vivo (living) models, it could allow clinicians to determine within days whether a specific targeted therapy is working, enabling faster adjustments to treatment plans and potentially improving outcomes for patients with aggressive gliomas.

Key Terms and Definitions

2H-MRS (Deuterium Magnetic Resonance Spectroscopy) — An imaging technique that uses deuterated tracers to track metabolic pathways and chemical reactions within living cells or tissues.
PI3K/mTOR Inhibitor — A therapeutic agent that blocks the PI3K/mTOR signaling pathway, which is frequently overactive in cancer and drives cell growth and metabolism.
Neurospheres — Three-dimensional clusters of neural stem cells or cancer cells used in research to better replicate the complex environment of a brain tumor compared to standard flat-surface cell cultures.
Glycolytic Rate — The speed at which cells break down glucose to produce energy, a process often accelerated in cancer cells to support rapid proliferation.
Biomarker — A measurable indicator of a biological state or condition, used here to identify the early metabolic response of cancer cells to drug treatment.

Abstract

Motivation: Effective treatment response seen in paediatric-type diffuse high grade glioma with conventional MRI can take months to manifest. Goal(s): Evaluation of 2H-MRS for monitoring the metabolism of deuterated glucose in PDHGG cells and assessing early metabolic response to PI3K inhibition. Approach: PIK3R1 mutant neurospheres were treated with a dual PI3K/mTOR inhibitor for 72 and 24 hours, and 2H spectra dynamically acquired in the presence of [6,6-2H2]-glucose. Results: Treatment significantly reduced glycolytic rates at both timepoints. At 24 hours there was no difference in cell number or viability, highlighting the potential of 2H-MRS to provide an early biomarker of response. Impact: Establishing acute treatment-induced changes in the glycolytic rate of PDHGG neurospheres using 2H-MRS provides confidence in the sensitivity of deuterium metabolic imaging for assessing the early response of orthotopic PDHGG models to PI3K inhibition in vivo.

METABOLIC RESPONSE OF PAEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMA CELLS TO PI3K INHIBITION DETECTED BY 2H-MRS | Declan J. Bolster et al. | ResearchPod

METABOLIC RESPONSE OF PAEDIATRIC-TYPE DIFFUSE HIGH GRADE GLIOMA CELLS TO PI3K INHIBITION DETECTED BY 2H-MRS: Research Paper Podcast